These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 25669642)

  • 21. Optimizing trial design in pharmacogenetics research: comparing a fixed parallel group, group sequential, and adaptive selection design on sample size requirements.
    Boessen R; van der Baan F; Groenwold R; Egberts A; Klungel O; Grobbee D; Knol M; Roes K
    Pharm Stat; 2013; 12(6):366-74. PubMed ID: 24214896
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Personalized medicine prompts push to redesign clinical trials.
    Singer E
    Nat Med; 2005 May; 11(5):462. PubMed ID: 15875041
    [No Abstract]   [Full Text] [Related]  

  • 23. Metabolic phenotype prediction from genotyping data: a bottleneck for the implementation of pharmacogenetics in drug development and clinical practice.
    LLerena A; Peñas-Lledó EM
    Drug Metab Pers Ther; 2015 Sep; 30(3):143-5. PubMed ID: 26353178
    [No Abstract]   [Full Text] [Related]  

  • 24. Ethical considerations in industry-sponsored multiregional clinical trials.
    Ibia E; Binkowitz B; Saillot JL; Talerico S; Koerner C; Ferreira I; Agarwal A; Metz C; Maman M
    Pharm Stat; 2010; 9(3):230-41. PubMed ID: 20824884
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessment of regional treatment effect in a multiregional clinical trial.
    Tsong Y; Chang WJ; Dong X; Tsou HH
    J Biopharm Stat; 2012 Sep; 22(5):1019-36. PubMed ID: 22946947
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Approaches to Japanese dose evaluation in global drug development: factors that generate different dosages between Japan and the United States.
    Nakashima K; Narukawa M; Takeuchi M
    Clin Pharmacol Ther; 2011 Dec; 90(6):836-43. PubMed ID: 22048222
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacogenetics and pharmacogenomics: development, science, and translation.
    Weinshilboum RM; Wang L
    Annu Rev Genomics Hum Genet; 2006; 7():223-45. PubMed ID: 16948615
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Design and evaluation of multiregional trials with heterogeneous treatment effect across regions.
    Chen CT; Hung HM; Hsiao CF
    J Biopharm Stat; 2012 Sep; 22(5):1037-50. PubMed ID: 22946948
    [TBL] [Abstract][Full Text] [Related]  

  • 29. "Getting the dose right": facts, a blueprint, and encouragements.
    Peck CC; Cross JT
    Clin Pharmacol Ther; 2007 Jul; 82(1):12-4. PubMed ID: 17571068
    [No Abstract]   [Full Text] [Related]  

  • 30. Biomarker as a classifier in pharmacogenomics clinical trials: a tribute to 30th anniversary of PSI.
    Wang SJ
    Pharm Stat; 2007; 6(4):283-96. PubMed ID: 17957727
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Establishing consistency across all regions in a multi-regional clinical trial.
    Tsou HH; James Hung HM; Chen YM; Huang WS; Chang WJ; Hsiao CF
    Pharm Stat; 2012; 11(4):295-9. PubMed ID: 22504851
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Complex disease-associated pharmacogenetics: drug efficacy, drug safety, and confirmation of a pathogenetic hypothesis (Alzheimer's disease).
    Roses AD; Saunders AM; Huang Y; Strum J; Weisgraber KH; Mahley RW
    Pharmacogenomics J; 2007 Feb; 7(1):10-28. PubMed ID: 16770341
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ontogeny and drug metabolism in newborns.
    Dotta A; Chukhlantseva N
    J Matern Fetal Neonatal Med; 2012 Oct; 25 Suppl 4():83-4. PubMed ID: 22958028
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A question-based approach to adopting pharmacogenetics to understand risk for clinical variability in pharmacokinetics in early drug development.
    Evers R; Blanchard RL; Warner AW; Cutler D; Agrawal NG; Shaw PM
    Clin Pharmacol Ther; 2014 Sep; 96(3):291-5. PubMed ID: 25141952
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Translational approach for pharmacogenomics and personalized medicine].
    Zhang W; Zhou HH
    Yao Xue Xue Bao; 2011 Jan; 46(1):1-5. PubMed ID: 21465801
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Potential of adaptive clinical trial designs in pharmacogenetic research.
    van der Baan FH; Knol MJ; Klungel OH; Egberts AC; Grobbee DE; Roes KC
    Pharmacogenomics; 2012 Apr; 13(5):571-8. PubMed ID: 22462749
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Clinical-pharmacological aspects to accelerate the development process from the preclinical to the clinical phase/2nd communication: promising strategies].
    Kuhlmann J
    Arzneimittelforschung; 2004; 54(6):307-13. PubMed ID: 15282874
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Consideration of regional difference in design and analysis of multi-regional trials.
    Hung HM; Wang SJ; O'Neill RT
    Pharm Stat; 2010; 9(3):173-8. PubMed ID: 20872619
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Retrospective validation of genomic biomarkers-- what are the questions, challenges and strategies for developing useful relationships to clinical outcomes-- workshop summary.
    Wang SJ; Cohen N; Katz DA; Ruano G; Shaw PM; Spear B
    Pharmacogenomics J; 2006; 6(2):82-8. PubMed ID: 16402078
    [No Abstract]   [Full Text] [Related]  

  • 40. Pharmacogenetics at 50: genomic personalization comes of age.
    Urban TJ; Goldstein DB
    Sci Transl Med; 2014 Jan; 6(220):220ps1. PubMed ID: 24452261
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.